Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled time : 14:15 save search
Breast Implants Market size worth $ 2.02 Billion, Globally, by 2028 at 5.22% CAGR: Verified Market Research®
Published: 2021-11-11 (Crawled : 14:15) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
implant research market
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
rheumatoid arthritis response
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
Published: 2021-09-09 (Crawled : 14:15) - biospace.com/
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.27%
C: -1.98%
GMAB | News | $28.47 -0.32% -0.32% 430K
|
Health Technology
|
| O: -1.2%
H: 0.95%
C: -0.77%
trial t-cell lancet
A $138.8 Billion Global Opportunity for Nanotechnology in Drug Delivery by 2026 - New Research from StrategyR
Published: 2021-09-03 (Crawled : 14:15) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.75%
H: 0.8%
C: 0.4%
drug technology research drug delivery liver
AbbVie to Host Second-Quarter 2021 Earnings Conference Call
Published: 2021-07-07 (Crawled : 14:15) - biospace.com/
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.16%
H: 0.91%
C: 0.72%
conference
Global Facial Aesthetics Market to Witness $ 1.45 Billion growth during 2021-2025 | Technavio
Published: 2021-06-14 (Crawled : 14:15) - prnewswire.com
BHC | $8.56 0.35% 0.12% 2M
|
Health Technology
|
| O: 0.06%
H: 0.75%
C: -0.97%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.3%
H: 0.36%
C: 0.29%
ANIK | $25.9 0.43% 0.88% 31K
|
Health Technology
|
| O: -0.3%
H: 1.3%
C: -2.01%
aesthetic growth
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract
Published: 2021-05-12 (Crawled : 14:15) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.03%
H: 1.0%
C: 0.1%
XFOR | $1.29 4.88% 3.91% 1.6M
|
Health Technology
|
| O: -1.39%
H: 18.59%
C: 3.08%
ongoing phase 1 positive trial phase 1b phase 2b
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.